Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

55 results about "Joint synovium" patented technology

The synovium, also referred to as the synovial membrane, is the soft tissue that lines the spaces of diarthrodial joints, tendon sheaths, and bursae. The synovium lines the entire inner surface of the joint, except where the joint is lined with cartilage. The synovium has an outer layer (subintima) and an inner layer (intima).

Use of tetrahydroharman in the preparation of a medicament for the treatment of rheumatoid arthritis

ActiveCN119157878BOrganic active ingredientsAntipyreticSynovial hyperplasiaJoint damage
The present application belongs to the technical field of medicine, and particularly relates to the use of tetrahydrojatrorrhizine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating rheumatoid arthritis. Experimental results show that tetrahydrojatrorrhizine can effectively alleviate the foot swelling level of CIA rats, reduce the arthritis score, and inhibit the progression of rheumatoid arthritis. Blood routine analysis shows that the administration of tetrahydrojatrorrhizine reduces the number of immune cells in the blood and weakens the immune level of the body. In addition, the experimental results also show that tetrahydrojatrorrhizine can inhibit synovial hyperplasia and relieve joint damage. Therefore, tetrahydrojatrorrhizine has the prospect of being developed into an oral medicament for treating rheumatoid arthritis, provides more treatment options for clinically treating rheumatoid arthritis, and has important social and economic values.
Owner:PEKING UNIV

Lindera glauca extract, preparation method thereof and application of lindera glauca extract in preparation of medicine for preventing and / or treating rheumatoid arthritis

The invention discloses a lindera glauca extract, a preparation method thereof and application of the lindera glauca extract in preparation of drugs for preventing and / or treating rheumatoid arthritis. The research finds that the lindera glauca extract can obviously reverse arthritic rat plantar part swelling and toe bending, relieve ankle joint injury, relieve synovial hyperplasia and inflammatory cell infiltration, inhibit joint fusion, relieve joint gap stenosis, relieve articular surface fusion tendency, increase bone mineral density and bone trabecula number, reduce bone trabecula separation degree and improve joint fusion. The lindera glauca extract can be used for relieving rheumatoid arthritis by protecting the inherent structure of joint tissues and improving inflammation, so that a novel natural medicine choice is provided for preventing and / or treating rheumatoid arthritis.
Owner:WUHAN CHINESE & WESTERN MEDICINE UNION HOSPITAL

WTAP as clinical diagnosis marker for rheumatoid arthritis and application of WTAP

The invention belongs to the technical field of biomedicine, and particularly relates to WTAP as a clinical diagnosis marker for rheumatoid arthritis and application of the WTAP. Experiments prove that the WTAP level in rheumatoid arthritis involved parts such as serum and synovial tissues of rheumatoid arthritis patients is remarkably higher than that of normal people, the WTAP and the rheumatoid arthritis are positively correlated, and the WTAP gene or WTAP protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of the rheumatoid arthritis; the CIA mouse with the WTAP gene knocked out shows that the illness state is relieved, and the symptoms are relieved, so that the WTAP can be used as an effective target for treating rheumatoid arthritis.
Owner:ANHUI MEDICAL UNIV

Application of BAY-069 in preparation of medicine for treating rheumatoid arthritis

The invention belongs to the technical field of medicines, and particularly relates to application of BAY-069 in preparation of a medicine for treating rheumatoid arthritis. Through metabonomics research, the inventor finds that the metabolic enzyme BCAT2 is remarkably highly expressed in synovial tissues of an active-stage RA patient and is relatively low in expression in synovial tissues of a remission-stage RA patient. The high expression of the metabolic enzyme BCAT2 is closely related to synovitis and bone destruction. The BAY-069 as a BCAT2 inhibitor can significantly reduce the score of joint inflammation, reduce synovitis and bone destruction, and effectively reduce bone loss. The invention provides an innovative RA metabolism targeted treatment strategy which has high safety and strong targeting property.
Owner:WUXI HOSPITAL OF CHINESE MEDICINE

Pharmaceutical preparation of macrophage-derived exosome loaded aconite decoction extract, preparation method and application thereof in preparation of drugs for preventing and treating osteoarthritis

PendingCN123024048AJoint synovialIn vitro test
The present application relates to the fields of medicine, modernization of traditional Chinese medicine and drug delivery, and specifically relates to a macrophage-derived exosome loaded with aconite decoction extract, a preparation method thereof and application thereof in preparation of a drug for preventing and treating osteoarthritis. The effective component of the drug preparation is macrophage-derived exosome loaded with aconite decoction extract, which includes low-loading preparation WTDL-Exos and high-loading preparation WTDH-Exos and contains pharmaceutically acceptable excipients. The macrophage-derived exosome is preferably derived from mouse macrophage RAW264.7 and is extracted through differential centrifugation and ultracentrifugation; the aconite decoction extract is prepared from prepared monkshood, astragalus, honeyed licorice, ephedra and peony, and the concentration of the aconite decoction mother liquor is 10 mg / mL; the drug-loaded exosome is obtained by co-incubation of the aconite decoction extract and the macrophage-derived exosome and purification, and the loading rate is about 20%. In vitro tests show that WTD-Exos has no obvious effect on cell survival rate and is basically non-cytotoxic. Western blot detection in animal experiments shows that the drug preparation can down-regulate the expression of MMP-13 and TNF-α in synovial tissue and up-regulate the expression of type II collagen, thereby improving joint synovial inflammation and protecting joint cartilage. The drug preparation can be used for preparing a drug for preventing and treating osteoarthritis.
Owner:CHONGQING MEDICAL UNIVERSITY

Rheumatoid arthritis hand auxiliary treatment sheath

The invention relates to the technical field of arthritis treatment jackets, in particular to a rheumatoid arthritis hand auxiliary treatment jacket which comprises a glove, the glove is divided into a palm face and a hand back face, a wrist is constructed on one side of the glove, and a pressure control piece is arranged on the glove; the pressure control part comprises a cavity constructed in the glove, the cavity divides the glove into an outer layer and an inner layer, the outer layer is made of a heat preservation material, and the inner layer is made of an elastic material; a water injection valve communicated with the cavity is arranged on the glove, and liquid is allowed to enter and exit from the cavity by opening and closing the water injection valve; the three pressure control modes of wrist air bag pressurization and hand movement dynamic pressurization are adjusted through the liquid medicine injection amount, a patient can autonomously select pressure gears according to the illness state and the scene, low-gear mild pressurization is conducted during daily office mild movement, slight aching pain is relieved, operation is not affected, middle-gear moderate pressurization is conducted when joint swelling pain is aggravated, and therefore the patient can feel more comfortable. During night rest, middle and low gears can be flexibly selected, and morning stiffness is relieved while constraint feeling is avoided.
Owner:SHANGLUO TRADITIONAL CHINESE MEDICINE HOSPITAL

Application of TRADD related reagent in rheumatoid arthritis related products

The invention relates to the technical field of biological medicine, in particular to application of a TRADD related reagent in rheumatoid arthritis related products. The invention finds that a TNFR1 signal channel is obviously enhanced in RA synovial tissues, and the expressions of TNFR1, TRAF2, TRADD and p65 are higher than those of normal synovial tissues, so that the invention provides the application of the reagent for detecting the expression of TRADD in the preparation of detection products for rheumatoid arthritis.
Owner:ANHUI MEDICAL UNIV

Application of MID1 as a marker and target for rheumatoid arthritis

The present application discloses the application of MID1 as a marker and target for rheumatoid arthritis. The present application discloses that MID1 can be used as a diagnostic marker and therapeutic target for rheumatoid arthritis. By detecting the expression level of MID1, it can be used to diagnose rheumatoid arthritis. By knocking down the expression of MID1, the proliferation, invasion and metastasis of synovial fibroblasts can be inhibited, the secretion of proinflammatory cytokines can be inhibited, and the incidence of collagen-induced arthritis can be reduced.
Owner:TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH

Use of dibenzazepine compounds in mistletoe for preparing a medicine for preventing or treating rheumatoid arthritis

PendingCN122140670APeptide/protein ingredientsHydroxy compound active ingredientsMistletoe lectinDibenzazepine
The application belongs to the technical field of natural medicinal chemistry, and relates to the use of a dibenzazepine compound in mistletoe in the preparation of a medicine for preventing or treating rheumatoid arthritis. In vitro experiments show that the use of the compound alone has different degrees of inhibitory effect on the proliferation of primary rat synovial fibroblasts, and the inhibitory effect is synergistically enhanced when the compound 2 is used in combination with mistletoe lectin. Animal experiments show that the use of the compound alone has different degrees of inhibitory effect on the joint swelling of a collagen-induced rat arthritis model, and the inhibitory effect of some dibenzazepine compounds is close to or better than that of a positive medicine, and the inhibitory effect of the compound 2 used in combination with mistletoe lectin on the joint swelling of the right hind foot of a rat is synergistically enhanced. In summary, the dibenzazepine compound in mistletoe has the potential to be developed into a medicine for treating rheumatoid arthritis, can provide more choices for clinical treatment, and has important social benefits and economic value.
Owner:HEILONGJIANG UNIV OF CHINESE MEDICINE

Preparation method and application of traditional Chinese medicine composition submicron emulsion

The invention discloses a preparation method and application of a traditional Chinese medicine composition submicron emulsion, and belongs to the technical field of traditional Chinese medicines. The invention discloses a submicron emulsion of a traditional Chinese medicine composition. The submicron emulsion comprises the following components: an ethanol extract of the traditional Chinese medicine composition, red-knees herb essential oil, grape seed oil, ginger oil, an emulsifier and methyl salicylate, the traditional Chinese medicine composition comprises the following components: gaultheria yunnanensis, cortex erythrinae, red-knees herb, semiliquidambar cathayensis, herba epimedii, pepper, helleborus thibetanus and loose knot. The invention also provides application of the traditional Chinese medicine composition submicron emulsion in preparation of medicines for treating rheumatoid arthritis of rats. Results show that the traditional Chinese medicine composition submicron emulsion provided by the invention can improve the swelling degree of rat bone joints, eliminate the red and swollen state, relieve infiltration of inflammatory cells to synovial tissues and infiltration of inflammatory cells to cartilage tissues, and has a remarkable treatment effect on rats with rheumatoid arthritis. Therefore, the traditional Chinese medicine composition submicron emulsion disclosed by the invention has certain development and application prospects.
Owner:THE KEY LAB OF CHEM FOR NATURAL PROD OF GUIZHOU PROVINCE & CHINESE ACADEMY OF SCI

Traditional Chinese medicine extract for preventing and treating rheumatoid arthritis

The invention relates to the field of traditional Chinese medicines, in particular to an active pharmaceutical ingredient for preventing and treating rheumatoid arthritis and a preparation method thereof. The traditional Chinese medicine extract, namely coix seed ester, disclosed by the invention has the effects of preventing and treating pain, numbness and soreness of limbs, joints, muscles and the like due to arthralgia syndromes as well as adverse flexion and extension, swelling and deformation of the joints and the like. Animal experiment research proves that the coix seed ester has a good improvement effect on treating a rat model with arthritis induced by collagen, and the coix seed ester can obviously inhibit synovial hyperplasia and formation of vascular nebula and inhibit inflammatory response of RA (rheumatoid arthritis). The idea of treating the RA by using the coix seed ester is based on the pathogenesis of phlegm-dampness formation in the traditional Chinese medicine theory and the inflammation mechanism of modern research, the traditional Chinese medicine and the western medicine are combined, and the important clinical significance is achieved for relieving the pain of patients and improving the life quality.
Owner:THE FIRST HOSPITAL OF CHINA MEDICIAL UNIV

Joint function-improving composition

An object is to provide a joint function-improving composition which is useful for prevention or treatment of various arthropathies such as osteoarthritis including knee osteoarthritis as a typical example and rheumatoid arthritis because the composition has an action of promoting growth of chondrocytes and an action of suppressing the production of an inflammation factor, a cartilage matrix degradation factor, a pain factor or a neuronal outgrowth factor by synoviocytes and to provide a joint function-improving product containing the composition such as a food or a drink, feed and a medicine. A joint function-improving composition containing bacterial cells and / or a culture of a bacterium belonging to genera Lactobacillus, Lactococcus, Streptococcus or Bifidobacterium and a joint function-improving agent, a joint function-improving food or drink, a joint function-improving nutritional composition, joint function-improving feed or a joint function-improving pharmaceutical agent which is characterized by containing the joint function-improving composition.
Owner:MEGMILK SNOW BRAND CO LTD

Effective part of podophyllum hexandrum and application of effective part in preparation of medicine for treating rheumatoid arthritis

The invention discloses an effective part of podophyllum hexandrum, which is a dichloromethane extraction part of an alcohol extract of podophyllum hexandrum rhizome. The dichloromethane extraction part of podophyllum hexandrum has a remarkable inhibition effect on FLS cells, and the podophyllum hexandrum dichloromethane extraction part is orally taken, so that the foot swelling degree and joint injury of RA rats can be relieved in a dose-dependent manner, and the levels of various inflammatory factors in blood and synovial tissues are inhibited. The invention discloses application of the podophyllum hexandrum effective part in preparation of a medicine for treating rheumatoid arthritis.
Owner:THE SECOND AFFILIATED HOSPITAL TO NANCHANG UNIV

Use of a pharmaceutical composition for the preparation of a medicament for the treatment of rheumatoid arthritis

The application discloses application of a medicine composition in preparation of a medicine for treating rheumatoid arthritis (RA), and belongs to the field of RA treating medicines. The medicine composition is composed of swertiamarin (SW) and neochlorogenic acid (NCA) and is screened from two active ingredients in Danteng Yimu Decoction. With the help of animal model and cell model experiments, the action mechanism of the medicine composition in treating RA is explored, the related symptoms and indexes of collagen-induced arthritis (CIA) rats can be effectively improved, joint swelling can be relieved, arthritis inflammation index can be reduced, inflammatory factor release can be inhibited, joint bone quality can be protected, arthritis inflammation infiltration and cartilage destruction can be reduced, and the medicine safety is good. The composition can effectively inhibit the inflammatory factor release and migration ability of rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS). Animal experiments and cell experiments prove that the combination of neochlorogenic acid and swertiamarin (SW+NCA) can be effectively applied to clinical treatment of RA and has a wide application prospect.
Owner:CHINESE MEDICINE GUANGDONG LABORATORY +1

Rheumatoid arthritis early-stage AI intelligent diagnosis system based on multi-modal data fusion

The invention discloses a multi-modal data fusion-based rheumatoid arthritis early-stage AI intelligent diagnosis system, belongs to the technical field of medical artificial intelligence, and aims to solve the problems that in the prior art, RA early-stage diagnosis lags behind, the rate of missed diagnosis of serum negative patients is high, and risk assessment lacks quantitative standards. Comprising a multi-source data acquisition module, a data preprocessing module, a cross-modal fusion module, a dynamic time sequence model and a risk assessment module which are connected in sequence, according to the system provided by the invention, a dynamic tracking model of serological change-synovial inflammation-bone structure change is innovatively constructed, and an RA diagnosis window is advanced compared with that of a traditional method (depending on clinical symptoms) by capturing time sequence correlation of the serological change, the synovial inflammation and the bone structure change; aiming at the diagnosis difficulty of serum-negative RA, the system realizes great improvement of diagnosis performance through deep fusion of multi-modal features, serological core indexes, ultrasonic synovial dynamic features and X-ray bone microscopic features.
Owner:THE FIRST AFFILIATED HOSPITAL OF JINZHOU MEDICAL UNIV

Pain relievers for osteoarthritis of the knee and periarthritis of the shoulder

To provide novel drugs effective in improving pain associated with osteoarthritis of the knee and periarthritis of the shoulder. [Solution] According to the present invention, a synovial pain reliever for arthritis is provided, comprising an endothelin A receptor antagonist as an active ingredient, wherein the arthritis is osteoarthritis of the knee or periarthritis of the shoulder. According to the present invention, it is possible to improve joint pain caused by movements that put a load on the knee joint and joint pain at rest in patients with osteoarthritis of the knee, and it is possible to improve joint pain caused by movements that put a load on the shoulder joint and joint pain at rest in patients with periarthritis of the shoulder.
Owner:THE UNIV OF TOKYO +1

Use of myrtenol in the preparation of a medicament for the prevention and / or treatment of rheumatoid arthritis

The application discloses application of myrtenal in preparation of a medicine for preventing and / or treating rheumatoid arthritis. The application verifies for the first time that myrtenal can block the RA inflammatory cascade from multiple aspects, and overcomes the limitation that single-target treatment is easy to produce drug resistance. Specifically, myrtenal can reduce the levels of inflammatory factors and metal proteins; inhibit the proliferation, migration and invasion of synovial fibroblasts SFs; inhibit the expression of glycolysis-related genes, reduce sugar metabolites; inhibit the synovial tissue hyperplasia, inflammatory cell infiltration, bone erosion and bone destruction of mice joints; promote the mental state of arthritis mice to be obviously improved, the food intake to be increased, the hair to be shiny, the joint swelling to be subsided, the bruise of the ankle joint to be subsided, the skin to be improved, and the activity to be sensitive. Therefore, the application proposes a new medical use of myrtenal in treating rheumatoid arthritis, and develops a brand-new therapeutic indication of myrtenal.
Owner:SOUTH CHINA BOTANICAL GARDEN CHINESE ACADEMY OF SCI +1

Application of Chinese medicine composition in preparing medicine for preventing and treating gouty arthritis

The present invention provides an application of a Chinese medicine composition in the preparation of a medicine for preventing and treating gouty arthritis; the Chinese medicine composition comprises the following active ingredients: bupleurum, ganoderma lucidum, salvia miltiorrhiza, and schisandra chinensis. The present invention verifies through animal experiments that the above-mentioned Chinese medicine composition has a certain inhibitory effect on inflammatory factors in serum and has a relieving effect on the pain of rats with acute gouty arthritis. It can improve the joint swelling of rats with acute gouty arthritis, significantly reduce the level of inflammatory factors in rat serum, relieve the pain of rats, and improve the infiltration of inflammatory cells in the synovial tissue of the joints, indicating that the above-mentioned Chinese medicine composition has a certain anti-inflammatory and analgesic effect on acute gouty arthritis.
Owner:TSING HUA DE REN XIAN HAPPINESS PHARMA

A nano-drug for treating rheumatoid arthritis and a preparation method thereof

The application discloses a kind of nanomedicine for treating rheumatoid arthritis, including triptolide, Y6 fluorescent probe and poloxamer, triptolide and Y6 fluorescent probe are polymerized by poloxamer to form triptolide nanomedicine Y6@TPL, the average particle size of the triptolide nanomedicine Y6@TPL is 20~300nm.The application combines triptolide with Y6 fluorescent probe, constructs a new type of nano delivery system, the system not only realizes the accurate control release of drug, but also can be enhanced by photo-thermal response Targeted accumulation of rheumatoid arthritis lesion site, significantly improve the selective killing effect of triptolide on inflammatory synoviocytes, while greatly reducing the toxic side effects on normal joint tissue.The nano system integrates photo-thermal therapy, photo-thermal imaging and targeted drug delivery functions, and provides an integrated solution for the diagnosis and treatment of RA.
Owner:ZHEJIANG CHINESE MEDICAL UNIVERSITY

Nano-drug for treating rheumatoid arthritis and preparation method thereof

The invention discloses a nano-drug for treating rheumatoid arthritis, the nano-drug comprises triptolide, a Y6 fluorescent probe and poloxamer, the triptolide and the Y6 fluorescent probe are polymerized by the poloxamer to form a triptolide nano-drug Y6 at TPL, and the average particle size of the triptolide nano-drug Y6 at TPL is 20-300 nm. The triptolide and the Y6 fluorescent probe are combined to construct a novel nano delivery system, the system not only realizes precise controlled release of drugs, but also can enhance targeted accumulation of rheumatoid arthritis focus parts through photo-thermal response, the selective killing effect of the triptolide on inflammatory synovial cells is remarkably improved, and the application prospect is broad. Meanwhile, the toxic and side effects on normal joint tissues are greatly reduced. According to the nano system, photo-thermal treatment, photo-thermal imaging and targeted drug delivery functions are integrated, and an integrated solution is provided for diagnosis and treatment of RA.
Owner:ZHEJIANG CHINESE MEDICAL UNIVERSITY

Neuro-integrated bioreactor system for studying joint pain and treatment thereof

Disclosed herein are various bioreactor devices that mimic the mammalian joint. The bioreactor device includes a series of bioreactor chambers that contain different components of the joint, such as bone, cartilage, synovium, and ligament, and which are integrated with neural processes to better recapitulate physiological conditions, including joint pain. At least two different nutrient fluid circulation systems connect subsets of the bioreactor chambers to differentially supply nutrient fluids at concentrations optimized for the tissue that the fluid nourishes. The disclosed bioreactor devices enable interrogation of the interplay between the peripheral nervous system and joint tissues. By recording activity in sensory neurons, joint integrity as well as therapeutic efficacy can be monitored in real time.
Owner:UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION

Joint synovial cavity endoscope device

The invention relates to the technical field of endoscopes, in particular to a joint synovial cavity endoscope device which comprises an outer shell, a grab handle, a supporting pad, a driving part, a moving plate, an adjusting part, a connecting rod, an adjusting plate, a micro camera and a light source system. The connecting rod is driven by the adjusting piece to rotate along the axis of the connecting rod, so that the adjusting plate can be driven to rotate along the axis of the connecting rod, and then the micro camera and the light source system can be driven to rotate along the axis of the connecting rod. The angle of the micro camera is adjusted, the micro camera can observe the diseased region of a patient in all directions by adjusting the position and the angle of the micro camera, and therefore medical staff can obtain a more comprehensive operation view field, and the use effect of the endoscope is improved.
Owner:LUKA (CHONGQING) MEDICAL EQUIP CO LTD

Jinhuang powder external application paste and application thereof in preparation of medicine for treating gonitis synovitis

PendingCN122056990AAntipyreticAnalgesicsOfficinalisLysholm score
The invention discloses a Jinhuang powder external application paste and application thereof in preparation of drugs for treating gonitis synovitis, the external application paste is prepared from ten traditional Chinese medicines including turmeric, rheum officinale, golden cypress, radix angelicae, rhizoma arisaematis, pericarpium citri reticulatae, rhizoma atractylodis, mangnolia officinalis, liquorice and radices trichosanthis, honey, edible vegetable oil, paraffin oil and water through a specific emulsification process, the pH value is 6.0-7.0, and the viscosity is 3000-5000 mPa.s; standard random control clinical tests prove that the total effective rate of the external application ointment for treating gonarthromeningitis reaches 99.04%, the Lyshilm score is improved by 30.2 score, the VAS score is reduced by 5.39 score and is greatly superior to that of a diclofenac sodium control group, the adverse reaction occurrence rate is only 3.85%, the levels of serum TNF-alpha, IL-1beta and IL-6 and the synovial thickness can be greatly reduced, and the external application ointment has a good clinical application prospect. The method is suitable for K-L grading I-II and postoperative rehabilitation patients.
Owner:李建

Application of rotigotine microspheres in preparation of medicine for preventing and treating rheumatoid arthritis

The invention discloses an application of rotigotine microspheres in preparation of medicines for preventing or treating rheumatic arthritis, the rotigotine microspheres can directly act on joint parts, joint synovial hyperplasia, joint injury and bone erosion are effectively reduced, and the curative effect of the rotigotine microspheres is improved. The rotigotine microspheres can be independently used or matched with other known medicines, compounds or carriers to be prepared into various forms of medicaments or pharmaceutical compositions for prevention or treatment, and the dopamine receptor can be continuously excited for 4-8 weeks by injecting once during administration, so that the'on-off 'phenomenon caused by fluctuation of blood concentration is remarkably improved, and the bioavailability of the rotigotine microspheres is improved. Therefore, the curative effect can be effectively improved, and the compliance of a patient is greatly improved.
Owner:YANTAI UNIV

USE OF GsMTx4 AND GsMTx4 CONJUGATES TO IMPROVE RECOVERY FROM JOINT INJURY

The invention provides methods and products to reduce one or more symptoms from injury to a synovial joint. The methods and products relate to injecting into or around cartilage of the synovial joint the peptide GsMTx4 or a composition targeting GsMTx4 to the cartilage. The synovial joint can be, for example, a knee joint, shoulder joint, hip joint, or a facet joint of the spine.
Owner:UNIVERSITY OF ROCHESTER

Use of PT-129 in the preparation of a medicament for treating rheumatoid arthritis

This invention discloses the application of PT-129 in the preparation of drugs for treating rheumatoid arthritis (RA), belonging to the field of RA treatment. This invention is the first to demonstrate that the compound PT-129 can target and intervene in the synovial microenvironment, effectively inhibiting the abnormal activation behaviors of RA fibroblast-like synovial cells (FLS) such as proliferation, migration, and invasion, and downregulating the expression of N-cadherin and MMP3 proteins in synovial tissue. This invention provides a combined drug formulation containing PT-129 and RGFP966. This composition exhibits a significant synergistic effect in vivo, effectively relieving joint swelling, increasing bone density and trabecular bone thickness, reducing trabecular bone separation, thereby inhibiting cartilage degradation and bone destruction. This invention provides a novel targeted drug and combination therapy with definite efficacy for the clinical intervention of RA, possessing extremely high clinical application development value.
Owner:THE SECOND AFFILIATED HOSPITAL OF ANHUI MEDICAL UNIV

Use of psoralidin in preparation of drugs for preventing and treating rheumatoid arthritis

PendingCN122351227AEfficacyPharmaceutical drug
This invention belongs to the field of pharmaceutical technology, specifically relating to the application of psoralen in the preparation of drugs for the prevention and treatment of rheumatoid arthritis. This invention aims to address the problem of insufficient efficacy and inadequate clinical needs of existing rheumatoid arthritis prevention and treatment drugs, filling the technological gap in the pharmacological activity of psoralen against rheumatoid arthritis. Studies have confirmed that psoralen can effectively inhibit the secretion of IL-6 and IL-8 by RA-FLS cells, effectively inhibit RA-FLS cell proliferation, migration, and invasion, significantly improve joint swelling and weight loss symptoms in CIA mice, effectively regulate immune imbalance, and effectively repair joint pathological damage. It blocks the pathological processes of rheumatoid arthritis, including inflammation, immune disorders, synovial damage, and bone destruction, from multiple pathways and dimensions. Furthermore, psoralen is a natural plant-derived component. This invention provides a novel natural drug option for the treatment of rheumatoid arthritis, effectively improving the existing treatment system for the disease.
Owner:INSTITUTE OF CHINESE MATERIA MEDICA CHINA ACADEMY OF CHINESE MEDICAL SCIENCES

Use of sema3e protein in preparation of drugs for treating rheumatoid arthritis and promoting cartilage regeneration

The application provides application of SEMA3E protein in preparation of a drug for treating rheumatoid arthritis and promoting cartilage regeneration, and belongs to the technical field of biological medicine. The amino acid sequence of the SEMA3E protein is shown as SEQ ID No. 1. Research results show that one month after injection of the SEMA3E protein solution, the joint swelling degree of the double hind limbs of an animal model is reduced, the joint space and integrity are restored to normal, the cartilage thickness is increased, and the phenomenon of synovial cell infiltration and invasion into the cartilage is eliminated. That is, the SEMA3E protein can well reduce joint cavity inflammation and improve damaged joints.
Owner:KUNMING UNIV OF SCI & TECH

Application of tetrahydrojateorhizine in preparation of medicine for treating rheumatoid arthritis

ActiveCN119157878AOrganic active ingredientsAntipyreticOral medicineSynovial hyperplasia
The invention belongs to the technical field of medicines, and particularly relates to application of tetrahydrojateorhizine or pharmaceutically acceptable salt thereof in preparation of medicines for treating rheumatoid arthritis. Experimental results show that tetrahydrojateorhizine can effectively relieve the foot swelling level of CIA rats, reduce the arthritis score and inhibit the progress of rheumatoid arthritis. Blood routine analysis shows that the number of immune cells in blood is reduced and the immune level of an organism is weakened by administration of tetrahydrojateorhizine. In addition, experimental results also show that tetrahydrojateorhizine can inhibit synovial hyperplasia and relieve joint injury. Therefore, the tetrahydrojateorhizine has the prospect of being developed into the oral medicine for treating the rheumatoid arthritis, provides more treatment choices for clinically treating the rheumatoid arthritis, and has important social benefits and economic values.
Owner:PEKING UNIV

A method for constructing a spontaneous rheumatoid arthritis animal model and application thereof

The application discloses a method for constructing a spontaneous rheumatoid arthritis animal model, and the rheumatoid arthritis phenotype of the mouse is spontaneously generated by knocking out PPARgamma in the skin keratinocytes of the joint part, including joint swelling, joint synovial thickening, inflammatory cell infiltration, anti-cyclic citrullinated polypeptide antibody increase, and rheumatoid factor increase, so that the clinical symptoms of the rheumatoid arthritis are simulated, and an important tool is provided for the related research of the rheumatoid arthritis.
Owner:HOSPITAL OF DERMATOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES